Advanced HIV disease in the Botswana combination prevention project: prevalence, risk factors, and outcomes.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
pubmed:
23
7
2020
medline:
18
2
2021
entrez:
23
7
2020
Statut:
ppublish
Résumé
To determine the proportion of individuals linking to HIV-care with advanced HIV-disease (CD4 cell counts ≤200 cells/μl) in the Botswana Combination Prevention Project, describe the characteristics of these individuals, and examine treatment outcomes. A subanalysis of a cluster-randomized HIV-prevention trial. HIV status was assessed in 16-64-year-olds through home and mobile testing. All HIV-positive persons not on antiretroviral therapy were referred to local Ministry of Health and Wellness clinics for treatment. Analysis was restricted to the 15 intervention clusters. The proportion of individuals with advanced HIV disease was determined; associations between advanced HIV disease and sex and age explored; and rates of viral suppression determined at 1-year. Mortality and retention in care were compared between CD4 strata (CD4 cell counts ≤200 vs. >200 cells/μl). Overall, 17.2% [430/2499; 95% confidence interval (CI) 15.7-18.8%] of study participants had advanced HIV disease (CD4 cell counts ≤200 cells/μl) at time of clinic linkage. Men were significantly more likely to present with CD4 cell counts 200 cells/μl or less than women [23.7 vs. 13.4%, adjusted odds ratio 1.9, 95% CI 1.5-2.3]. The risk of advanced HIV disease increased with increasing age (adjusted odds ratio 2.2, 95% CI 1.4-3.2 >35 vs. <25 years). Patients with CD4 cell counts 200 cells/μl or less had significantly higher rates of attrition from care during follow-up (hazards ratio 1.47, 95% CI 1.1-2.1). Advanced HIV disease due to late presentation to or disengagement from antiretroviral therapy care remains common in the Treat All era in Botswana, calling for innovative testing, linkage, and treatment strategies to engage and retain harder-to-reach populations in care.
Identifiants
pubmed: 32694412
doi: 10.1097/QAD.0000000000002627
pii: 00002030-202012010-00006
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2223-2230Subventions
Organisme : NIAID NIH HHS
ID : K24 AI131928
Pays : United States
Organisme : CGH CDC HHS
ID : U01 GH000447
Pays : United States
Organisme : CGH CDC HHS
ID : U2G GH001911
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Rcommendations for a public health approach. 2nd ed. Geneva: WHO; 2016. Available at: https://www.who.int/hiv/pub/arv/arv-2016/en/. [Accessed 12 November 2019]
UNAIDS. 90–90–90 – An ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2014. Available at: https://www.unaids.org/en/resources/documents/2017/90-90-90. [Accessed 12 November 2019]
Gaolathe T, Wirth KE, Holme MP, Makhema J, Moyo S, Chakalisa U, et al. Botswana's progress toward achieving the 2020 UNAIDS 90–90–90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV 2016; 3:e221–e230.
UNAIDS. Botswana 2018 country factsheet. Geneva: UNAIDS; 2018. Available at: https://www.unaids.org/en/regionscountries/countries/botswana. [Accessed 12 November 2019]
GBD 2015 HIV Collaborators. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV 2016; 3:e361–e387.
Makhema J, Wirth KE, Pretorius Holme M, Gaolathe T, Mmalane M, Kadima E, et al. Universal testing, expanded treatment, and incidence of HIV infection in Botswana. N Engl J Med 2019; 381:230–242.
Mupfumi L, Moyo S, Shin SS, Wang Q, Zetola N, Molebatsi K, et al. High incidence of tuberculosis in the first year of antiretroviral therapy in the Botswana National ART programme between 2011 and 2015. AIDS 2019; 33:2415–2422.
Tenforde MW, Mokomane M, Leeme T, Patel RKK, Lekwape N, Ramodimoosi C, et al. Advanced HIV disease in Botswana following successful antiretroviral therapy rollout: incidence of and temporal trends in cryptococcal meningitis. Clin Infect Dis 2017; 65:779–786.
Dryden-Peterson S, Medhin H, Kebabonye-Pusoentsi M, Seage GR, Suneja G, Kayembe MK, et al. Cancer incidence following expansion of HIV treatment in Botswana. PLoS One 2015; 10:e0135602.
Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339:966–971.
World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: WHO; 2017. Available at: https://www.who.int/hiv/pub/guidelines/advanced-HIV-disease/en/. [Accessed 12 November 2019]
Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N, Bisson GP, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One 2011; 6:e28691.
Botswana Ministry of Health. Handbook of the Botswana 2016 integrated HIV clinical care guidelines. Government of Botswana; 2016. Available at: www.moh.gov.bw/Publications/Handbook_HIV_treatment_guidelines.pdf. [Accessed 12 November 2019]
Walker AS, Prendergast AJ, Mugyenyi P, Munderi P, Hakim J, Kekitiinwa A, et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis 2012; 55:1707–1718.
Carmona S, Bor J, Nattey C, Maughan-Brown B, Maskew M, Fox MP, et al. Persistent high burden of advanced HIV disease among patients seeking care in South Africa's National HIV Program: data from a nationwide laboratory cohort. Clin Infect Dis 2018; 66: (Suppl_2): S111–S117.
Osler M, Hilderbrand K, Goemaere E, Ford N, Smith M, Meintjes G, et al. The continuing burden of advanced HIV disease over 10 years of increasing antiretroviral therapy coverage in South Africa. Clin Infect Dis 2018; 66: (Suppl_2): S118–S125.
Brennan AT, Maskew M, Larson BA, Tsikhutsu I, Bii M, Vezi L, et al. Who is seeking antiretroviral treatment for HIV now? Characteristics of patients presenting in Kenya and South Africa in 2017–2018. J Int AIDS Soc 2019; 22:e25358.
Patten GE, Cox V, Stinson K, Boulle AM, Wilkinson LS. Advanced HIV disease at antiretroviral therapy (ART) initiation despite implementation of expanded ART eligibility guidelines during 2007–2012 in Khayelitsha, South Africa. Clin Infect Dis 2014; 59:456–457.
Leeme TB, Mine M, Lechiile K, Mosepele M, Mphoyakgosi T, Muthoga C, et al. Utility of CD4 cell count monitoring in botswana: analysis of routine laboratory data.26th Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, WA; 2019.
Teasdale CA, Yuengling K, Preko P, Syowai M, Ndagije F, Rabkin M, et al. Persons living with HIV with advanced HIV disease: need for novel care models. J Int AIDS Soc 2018; 21:e25210.
Dovel K, Yeatman S, Watkins S, Poulin M. Men's heightened risk of AIDS-related death: the legacy of gendered HIV testing and treatment strategies. AIDS 2015; 29:1123–1125.
Nasuuna E, Tenforde MW, Muganzi A, Katunguuka E, Jarvis JN, Manabe YC, et al. Reduction in baseline CD4 count testing following HIV ‘Treat All’ adoption in Uganda clinics. Clin Infect Dis 2020; 5:ciaa261doi: 10.1093/cid/ciaa261 [Epub ahead of print].
doi: 10.1093/cid/ciaa261